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ENDOCRINOLOGY AND WOMEN’S 
SPORTS: THE DIAGNOSIS MATTERS 
RICHARD J. AUCHUS* 
INTRODUCTION 
The participation of women in sports, and in particular elite sports, is a 
relatively recent phenomenon starting at the turn of the twentieth century. 
Shortly after the establishment of women’s competitions in the Olympic Games, 
a few participants who were later found to be biologically male competed in these 
events.1 These instances led to efforts to police the entry criteria to the women’s 
events, but sport authorities soon recognized that a single dichotomous criterion 
for defining a “female” athlete was difficult to identify. 
In parallel with the rise of women’s sports, doping with performance-
enhancing substances, particularly androgens, began to plague elite sports 
starting in the 1950s. In an effort to preserve the safety and fairness of sport, 
extensive programs for anti-doping and testing have become a fixture of 
professional and now also recreational competitions. 
The East Germans quickly recognized that androgen doping was particularly 
effective in women, in whom androgen action could be raised from the low 
female status to higher male realms and beyond.2 Today, every elite athlete is 
subjected to rigorous testing for doping using sophisticated mass spectrometry 
systems that can cost roughly $1,000,000 with certified authentic standards and 
vigorous chain-of-custody documentation—testing far more technologically 
advanced than most non-athletes will ever receive in their medical care. 
Using these three points of reference as a framework, this Article will 
logically approach a discussion of sex in sport from the endocrinologist’s 
perspective. Part II will explain critical differences between male and female 
biology. Part III clarifies confusion resulting from the sex versus gender 
distinction. Part IV concludes that sex, and testosterone in particular, is 
fundamental to the discrepancies in athletic performance between men and 
women. Part V proposes solutions to defining the women’s category for the 
purposes of competitive sport. 
 
Copyright © 2018 by Richard J. Auchus. 
This article is also available at http://lcp.law.duke.edu/. 
* Departments of Pharmacology and Internal Medicine, Division of Metabolism, Endocrinology and 
Diabetes, University of Michigan, Ann Arbor, MI 48109. 
 1. See Joanna Harper, Athletic Gender, 80 LAW & CONTEMP. PROBS., no. 4, 2017, at 140–42 
(pointing to early debates about who should compete in the women’s category based on the participation 
of intersex and transgender athletes).   
 2. See Doriane Lambelet Coleman, Sex in Sport, 80 LAW & CONTEMP. PROBS., no. 4, 2017, at 72–
74 (depicting testosterone reference ranges for genetic males and females).   
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II 
DIFFERENCES IN MALE AND FEMALE PHYSIOLOGY 
A. Human Androgen Biology 
1. Sexual Differentiation 
Early studies, like Alfred Jost’s pioneering work in rabbits, sought to define 
the mechanisms of external genitalia formation,3 but subsequent studies 
illuminated the totality of androgen biology. Jost demonstrated that a secretion 
from the testis was carried through the circulation as an endocrine hormone to 
cause fusion of the labia and formation of the penis. Jost reproduced this action 
with exogenous testosterone (T), confirming that T was the major circulating 
hormone required to cause male sexual differentiation of the external genitals.4 
What Jost did not know is that an enzyme in the prostate and genital skin, 5α-
reductase type 2 (5R2), was required to metabolize T to dihydrotestosterone 
(DHT), and it was DHT that elicited this action to form the prostate, scrotum, 
and penis.5 Jean Wilson, Jim Griffin, Mike McPhaul, David Russell, and Stefan 
Andersson in Dallas then went on to define the genetics and molecular biology 
of 5R2 and the androgen receptor (AR, also known as NR3C4), the latter of 
which mediates most if not all actions of T, DHT, and synthetic androgens. With 
colleagues from around the world, they identified genetically male patients with 
mutations in either the SRD5A2 gene encoding 5α-reductase type 26 or the AR 
gene,7 and these seminal studies form the basis of our knowledge about androgen 
biology. 
2. Disorders of Androgen Biology: Androgen Insensitivity and 5R2 
Deficiency 
AIS and 5R2 deficiency (5R2D) afford very different phenotypes: 
AIS patients appear phenotypically female at birth and feminize during 
puberty.8 They develop breasts but lack facial and body hair and—critical for our 
discussion—do not develop male-pattern upper-body muscular development 
 
 3. Alfred Jost, Recherches Sur la Differenciation Sexuelle de L’embryon de Lapin, 36 ARCHIVES 
D’ANATOMIE MICROSCOPIQUE 151 (1947).  
 4. See generally Alfred Jost et al., Studies on Sex Differentiation in Mammals, 29 RECENT 
PROGRESS HORMONE RES. 1 (1973); Coleman, supra note 2, at 73 (discussing the primary (reproductive) 
and secondary (phenotypic) characteristics caused by testosterone).  
 5. See Nicholas Bruchovsky & Jean D. Wilson, The Conversion of Testosterone to 5 -Androstan-17 -
ol-3-one by Rat Prostate in Vivo and in Vitro, 243 J. BIOLOGICAL CHEMISTRY 2012 (1968).  
 6. See Marco Marcelli, A Single Nucleotide Substitution Introduces a Premature Termination Codon 
into the Androgen Receptor Gene of a Patient with Receptor-Negative Androgen Resistance, 85 J. 
CLINICAL INVESTIGATION 1522 (1990).  
 7. See Anice E. Thigpen et al., Molecular Genetics of Steroid 5a-Reductase 2 Deficiency, 90 J. 
CLINICAL INVESTIGATION 799 (1992).  
 8. See Jean D. Wilson et al., Steroid 5a-Reductase 2 Deficiency, 14 ENDOCRINE REV. 577 (1993).   
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during puberty despite a rise of circulating T that reaches the normal male range.9 
In other words, the casual observer would easily identify these patients as female 
sex, despite the presence of a 46,XY karyotype and testes capable of normal male 
T production. 
The absence of DHT generation from normal circulating T concentrations in 
patients with 5R2D renders the external genitalia as phenotypically female at 
birth and typically results in female sex of rearing. In contrast to AIS, however, 
these patients respond normally to T production at puberty, with profound 
physiologic changes including voice deepening, facial and body hair growth, 
male-pattern upper-body muscle development, and male-pattern effects on the 
brain. 
Furthermore, the presence of the 5α-reductase type 1 isoenzyme in liver and 
other tissues allows for significant virilization of the external genitalia at puberty. 
Growth of the penis and descent of the testes into the (often bifid) scrotum 
occurs, and some individuals with this condition make sperm and have fathered 
children with assisted reproduction methods. A corollary is that the tissues are 
exposed to male T concentrations during various windows in fetal and neonatal 
life, which can induce genetic or epigenetic programming changes on tissues like 
brain, muscle, bone, and skin. In endocrinology nosology, 5R2D individuals are 
defined as undervirilized males,10 because they share all properties of normal 
male physiology with the exception of the external genitalia and Wolffian duct 
development. In fact, roughly half of these individuals who are not identified and 
treated prior to puberty change their gender to male, a profound testament to the 
potent actions of T as a hormone in multiple body tissues. 
The only conditions with similar virilization and high frequency of gender 
reversal during a virilizing puberty as 5R2D are 17β-hydroxysteroid 
dehydrogenase type 3 (17HSD3) deficiency,11 discussed below, and partial AIS. 
The enzyme 17HSD3 converts androstenedione to T in the testicular Leydig cells. 
The enzyme is only expressed in the Leydig cells of the testis and is the only 
human enzyme that efficiently converts androstenedione to T. Patients with 
partial AIS can have a spectrum of phenotypes from normal but infertile male to 
phenotypic female with some features of androgenization, and partial AIS 
patients are generally the most difficult to assign into a dichotomous sex category. 
 
 9. See James E. Griffin, Androgen Resistance—The Clinical and Molecular Spectrum, 326 NEW 
ENG. J. MED. 611 (1992).  
 10. Peter A. Lee et al., Consensus Statement on Management of Intersex Disorders, 118 PEDIATRICS 
e488 (2006), http://pediatrics.aappublications.org.proxy.lib.duke.edu/content/pediatrics/118/2/ 
e488.full.pdf [http://perma.cc/ET6F-TL4A].  
 11. See Wayne M. Geissler et al., Male Pseudohermaphroiditism Caused by Mutations of Testicular 
17 -Hydroxysteroid Dehydrogenase 3, 7 NATURE GENETICS 34 (1994) (“The phenotype of 17HSD3-
deficient males is similar to that of 5R2D in that both have male Wolffian-duct derived internal genitalia 
and external genitalia that are predominantly female in character, and in both conditions, masculinization 
occurs at puberty.”). 
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3. Disorders of Androgen Biology: 17β-Hydroxysteroid Dehydrogenase Type 
3 Deficiency 
Because 17HSD3 is only found in the testicular Leydig cells, the ovaries of 
normal women and nearly all women with ovarian-derived androgen excess 
states are not capable of producing sufficient T to yield normal male circulating 
concentrations. Circulating concentrations of T in normal women and men show 
no overlap: females typically have concentrations of less than 60 ng/dL (~2 
nmol/L),12 while males have concentrations of roughly 300–1200 ng/dL (~10-40 
nmol/L).13 In other words, T concentrations in normal males are five to twenty 
times higher than those in normal women, and there is no overlap in the normal 
ranges. Even women with severe polycystic ovary syndrome, which is the most 
common condition that endocrinologists will agree are “hyperandrogenemic 
women,” rarely show T concentrations >120 ng/dL (4 nmol/L).14 Because sex 
hormone-binding globulin, the major binding protein for T, is typically higher in 
women than in men, free and bioavailable T concentrations in normal men and 
women are even more disparate than total T concentrations, for which there is 
no overlap plus a large gap between normal ranges.15 For these reasons, the 
International Association of Athletics Federations (IAAF) established a policy 
in 2012 to use a serum T concentration <10 nmol/L to define a “female athlete.”16 
This cutoff, based on substantial data (see Section II.A.4), was rather generous, 
as this concentration is on the low end of T concentrations in average males and 
far exceeds the T levels found in even hyperandrogenemic women. However, this 
definition of female athlete is still based on sound endocrinology principles. 
4. Androgens in Elite Female Athletes 
Given the performance-enhancing properties of T, one might wonder if elite 
female athletes possess higher circulating T than normal women. This question 
was addressed at the 2011 IAAF championships in Daegu, and in fact >75% of 
these elite female athletes had serum T in or close to the normal female range 
and well below the normal male range.17 A subsequent study found that women 
in the highest tertile of T values performed better than those in the lowest tertile 
 
 12. Richard S. Legro et al., Evidence for a Genetic Basis for Hyperandrogenemia in Polycystic Ovary 
Syndrome, 95 PROC. NAT’L. ACAD. SCI. 14956 (1998).  
 13. Shalender Bhasin et al., Reference Ranges for Testosterone in Men Generated Using Liquid 
Chromatography Tandem Mass Spectrometry in a Community-Based Sample of Healthy Nonobese Young 
Men in the Framingham Heart Study and Applied to Three Geographically Distinct Cohorts, 96 J. 
CLINICAL ENDOCRINOLOGY & METABOLISM 2430 (2011).  
 14. Legro, supra note 12. 
 15. Coleman, supra note 2, at 72–74. 
 16. Neena A. Xavier & Janet B. McGill, Hyperandrogenism and Intersex Controversies in Women’s 
Olympics, 97 J. CLINICAL ENDOCRINOLOGY & METABOLISM 3902 (2012). 
 17. Stéphane Bermon et al., Serum Androgen Levels in Elite Female Athletes, 99 J. CLINICAL 
ENDOCRINOLOGY & METABOLISM 4328 (2014). 
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for a few sports like middle-distance running.18 In both studies, however, a 
disturbing number of outliers on the high end were observed,19 which cannot be 
explained by normal female physiology. Some of these women are doping with 
T, and other bear the endocrinology disorders that have generated the 
controversy. 
B. Androgens and Athletic Performance 
The evidence that T is a performance-enhancing substance is irrefutable. In a 
landmark study, for example, Bhasin et al. demonstrate that with or without 
exercise, use of the androgen T-enanthate at 600 mg/week profoundly increases 
muscle strength and size over a placebo in young healthy male athletes.20 The 
dose used in this initial study might be viewed as somewhat between physiologic 
and the astronomical amounts used in athletes for doping, but this same group of 
investigators then showed a continuous dose-response for T and muscle 
size/strength from castrate values through the female range to the male range and 
beyond.21 These data strongly support the prominence of T in the genesis of 
athletic advantage for men over women. Consider the following athletic 
advantages in men and their origins: 
1. Greater muscle size and strength: due to T, as shown in the studies of Bhasin and 
colleagues. 
2. Higher red blood cell mass: due to T, which induces erythropoietin expression and the 
~3% higher hematocrit in men versus women. 
3. Increased aggression: due to T, as shown in numerous studies of normal and castrate 
men, transgender men and women, and children. 
4. Lack of breasts: due to T, as T counteracts the effects of estrogen to induce breast 
development, as illustrated in AIS. 
5. Narrow hips: actually not due to T but rather due to lack of progesterone, which is 
derived from the ovaries following ovulation. This is not a male advantage derived 
from the testes but a female disadvantage derived from the ovaries. 
III 
SEX VERSUS GENDER 
Part of the confusion generated in recent cases derives from an obfuscation 
of the difference between sex and gender. “Sex” is biologically determined and 
not the prerogative of the individual, while “gender” is self-determined by each 
individual person. This Part will address each difference in turn. 
 
 18. Stéphane Bermon & Pierre-Yves Garnier, Serum Androgen Levels and Their Relation to 
Performance in Track and Field: Mass Spectrometry Results from 2127 Observations in Male and Female 
Elite Athletes, 51 BRITISH J. SPORTS MED. 1309 (2017). 
 19. See id. 
 20. Shalender Bhasin et al., The Effects of Supraphysiologic Doses of Testosterone on Muscle Size 
and Strength in Normal Men, 335 NEW ENG. J. MED. 1 (1996). 
 21. See Thomas W. Storer et al., Testosterone Dose-Dependently Increases Maximal Voluntary 
Strength and Leg Power, but Does Not Affect Fatigability or Specific Tension, 88 J. CLINICAL 
ENDOCRINOLOGY & METABOLISM 1478 (2003) (showing a linear correlation of muscle mass and 
strength gains with the testosterone enanthate does from 50 to 600 mg/week).   
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A. From Chromosomal Sex to Phenotypic Sex 
Our concept of sex dates back to the earliest historical records. Concepts of 
sex were firmly entrenched in medical science and society at the time when 
women’s sports were first introduced. Sex is an intrinsically fundamental 
property that we share with other vertebrates and most animal species, and sex 
forms the basis for reproduction and propagation of our species. Sex has several 
components: 
1. Chromosomal (Genetic) Sex 
In most human beings, a 46,XY chromosomal complement (karyotype) 
equates with male sex and 46,XX with female sex. “Sex reversal” occurs with the 
chromosomal sex is discordant with one of the following components of sex. 
2. Gonadal Sex 
A 46,XY chromosome component normally drives the bipotential gonads to 
develop into testes, while 46,XX affords ovarian development. Testes and ovaries 
can be completely functional, completely nonfunctional, or partially functional. 
For example, in Klinefelter’s syndrome (46,XXY), the testes can make normal 
amounts of T during puberty but typically do not produce sperm and lose T 
synthesis capacity over time. Finally, ovotestes exist in true hermaphrodites with 
a spectrum of functional qualities. 
3. Phenotypic Sex 
At birth, only the external genitalia distinguish boys from girls 
phenotypically. The internal (Müllerian and Wolffian) structures are also 
sexually dimorphic, but these are not evaluated in most newborns. Because of 
differences in genetics and in T exposure during fetal life, however, some priming 
or influence on various organs has already occurred, which manifests later in 
adolescence and adulthood. At puberty, secondary sexual characteristics 
progress: breast development and pelvic widening in females versus further 
growth of the penis, facial and body hair, and upper-body musculature in males. 
A limited amount of contrasexual characteristics are common, like some sparse 
facial hair in girls or breast budding in boys, but these changes normally stabilize 
or regress as puberty progresses and the secondary sexual characteristics 
expected for the chromosomal sex dominate. 
Discordance of genetic and phenotypic sex have been grouped under the 
terminology “Disorders of Sex Development” or “Differences in Sex 
Development” (DSD),22 which replaces the previous “Intersex” or 
“Pseudohermaphroditism” terms. Although many affected patients and their 
families dislike these terms, this article will use the term DSD to be consistent 
with current norms—but with apologies for lack of a better and accepted option 
for this sensitive topic. Because androgens exert an active effect on multiple 
 
 22. Peter A. Lee et al., Global Disorders of Sex Development Update Since 2006: Perceptions, 
Approach and Care, 85 HORMONE RES. PAEDIATRICS 158 (2016).  
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organ systems to drive the constitutive female phenotype to the male phenotype, 
DSD diagnoses are grouped based on chromosomal sex. Thus, the two largest 
groups are 46,XY DSD (“undervirilized male”) and 46,XX DSD (“virilized 
female”). In fact, the aforementioned Daegu study on T levels of elite female 
athletes at the 2011 IAAF Championships, demonstrated that the prevalence of 
DSD is seven per 1,000 (consisting of both 46,XY DSD and 46,XX DSD) among 
athletes in elite women’s competition, a 140-fold increase from the general 
population. This staggering increase reflects the advantage that intermediate T 
values provide over the low values found in normal women. The most 
conspicuous DSD in this group is those athletes with 5R2D,23 who were reared as 
females and not diagnosed before entering elite competition. 
4. Sex of Rearing 
Parents are entrusted with the tasks of naming their babies and rearing them 
in society, and for most societies, this trajectory includes a dichotomous sex of 
rearing (boy/girl). As expounded below, this dichotomy is not only artificial and 
inadequate for human biology but also reflects a gender of rearing, although the 
choice is based primarily on the phenotypic sex and in particular the external 
genitalia. When these structures are not clearly normal female or male, it is the 
standard of care to determine the diagnosis leading to this condition. Not only 
does the diagnosis allow for proper treatment, like corticosteroid replacement for 
girls with 21-hydroxylase deficiency (21OHD), but also for the opportunity to 
counsel the family about the natural history of the disorder and the statistics 
about sex steroid production and sexual maturation, fertility, risk of gonadal 
malignancy, and other associated conditions. The diagnosis is critical for making 
treatment recommendations and framing expectations for the family in the best 
interests of the child. 
B. Components of Gender 
In contrast to sex, gender is self-determined—only the individual can define 
their gender, which is reflected in the individual’s interactions with other people 
in society.24 About 0.5-1% of people in the United States report being 
transgender, which means that they are living in a gender different from their 
natal sex and sex of rearing. Constructions of gender and behavioral aspects of 
gender as different from sex are also found in ancient cultures. In contrast, the 
biological basis of gender and complexity of a gender spectrum distinct from sex 
did not appear in the medical literature until well after Jost’s publications on 
 
 23. Patrick Fénichel et al., Molecular Diagnosis of 5 -Reductase Deficiency in 4 Elite Young Female 
Athletes Through Hormonal Screening for Hyperandrogenism, 98 J. CLINICAL ENDOCRINOLOGY & 
METABOLISM E1055 (2013), https://www.ncbi.nlm.nih.gov/pubmed/23633205 [https://perma.cc/X37Y-
2WPA] (follow link to full text article at Endocrine Society).  
 24. See Wylie C. Hembree et al., Endocrine Treatment of Transsexual Persons: An Endocrine Society 
Clinical Practice Guideline, 94 J. CLINICAL ENDOCRINOLOGY & METABOLISM 3132 (2009) (“Gender 
identity is used to describe a person’s fundamental sense of being a man, a woman, or of various 
indeterminate and flexible genders.”). 
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sexual differentiation.25 We now recognize that, just as DSD or intersex patients 
exist, gender is hardly dichotomous and exists as a spectrum, with some 
individuals living squarely in various intermediate genders or being gender-fluid, 
not embracing either dichotomous gender, or vacillating between genders based 
on situation. Sex and gender are concordant and dichotomous in most 
individuals, which is consistent with a strong influence of androgens and 
estrogens; however, the causality is far from complete or universal amongst 
individuals. As an extreme example, there is at least one well-described case of a 
patient with complete AIS (and therefore female phenotype) but firmly male 
gender.26 This individual could not develop male secondary sex (gender-
confirming) characteristics despite high-dose T treatment and required surgical 
construction of a penis equivalent. 
C. Care of Transgender Individuals 
The care of transgender individuals illustrates the proper medical handling of 
discordance between sex and gender. The standard of care for a male-to-female 
trans woman is medical or surgical suppression of T exposure plus estrogen 
replacement. The institution of gender-concordant hormone therapy with 
development of gender-affirming secondary sexual characteristics eliminates 
nearly 99% of the mood disturbances and tendency for personal harm that 
transgender individuals suffer without proper endocrine care—with or without 
gender-affirming surgeries to further enhance their phenotype.27 For a trans 
woman athlete, the treatment is no different, and World Anti-Doping Agency 
(WADA) policy specifies lowering T to <10 nmol/L for entering the women’s 
competition. Not surprisingly, a high fraction of these athletes fail to achieve this 
goal, despite access to means, given the performance enhancement of higher T. 
Conversely, female-to-male trans men receive T replacement under a therapeutic 
use exemption and compete against the men. Here, we find little controversy and 
accusations for trans men because natal men have comparable T exposure. 
 
 
 
 
 25. See Joshua D. Safer & Vin Tangpricha, Out of the shadows: It Is Time to Mainstream Treatment 
for Transgender Patients, 94 ENDOCRINE PRAC. 2485R (2008) (noting the lack of conventional medical 
care for transgender patients).   
 26. Guy T’Sjoen et al., Male Gender Identity in Complete Androgen Insensitivity Syndrome, 40 
ARCHIVES SEXUAL BEHAV. 635 (2011).  
 27. Gunter Heylens et al., Effects of Different Steps in Gender Reassignment Therapy on 
Psychopathology: A Prospective Study of Persons with a Gender Identity Disorder, 11 J. SEX MED. 119 
(2014). 
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IV 
WHAT CAN WE CONCLUDE? 
Based on the principles presented here, an endocrinologist concludes the 
following: 
A. The women’s competition must be defined by sex, not gender 
There is no logical reason to separate competitions on the self-determined 
and potentially fluid parameter of gender, which provides little intrinsic 
contribution to athletic performance. In contrast, this article illustrates how sex 
and, in particular, differences in T production is fundamental to the discrepancies 
in athletic performance typical of men and women. 
B. Gender must be respected 
We cannot force an athlete to change or present with a different gender just 
to compete, and all athletes must be allowed to compete as themselves. This 
principle will require sport and society to be more accepting of the modern 
concepts of gender and the gender spectrum. We will have to become 
comfortable with men (gender) competing in women’s (sex) events because that 
is their biology; with women (gender) competing in the men’s (sex) events 
because that is their biology; and with genderless or gender-fluid individuals in 
both competitions based on their biology. 
C. The diagnosis matters 
We use medical science to train athletes, detect doping, and care for 
transgender athletes. What would an endocrinologist do for a DSD patient who 
is not an athlete? We would determine the diagnosis and recommend appropriate 
therapy—that is the standard of care. The standard of care should be no different 
if the patient is an elite athlete. 
D. Athletes with testes, male T production and normal androgen receptors do 
not belong in the women’s competition 
If we are going to have a “women’s” competition, it is incomprehensible that 
patients with 5RD2 are allowed to compete against athletes with normal female 
T values. These athletes are male by every physiologic measure including all 
those that lead to the male advantages in sport, except atypical external genitalia 
and impaired fertility, which if anything would provide even greater advantages 
for athletic performance. While the triaging of athletes with some conditions 
might be difficult from a scientific perspective, those with 5RD2 are 
unequivocally male. 
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E. Athletes with ovaries but higher-than-normal T 
The majority of these cases will have some form of virilizing congenital 
adrenal hyperplasia like classic or nonclassic 21OHD.28 It is likely that the 
prevalence of nonclassic 21OHD in elite women’s sports is far higher than the 
seven per 1,000 figure for DSD. T values for untreated nonclassic 21OHD 
patients are still well below the male range, whereas classic 21OHD women in 
very poor control can have T values encroaching into the male range. The flip 
side for women with classic 21OHD is that the more severe the condition and the 
higher their T, the lower their cortisol—they have adrenal insufficiency. It is the 
standard of care to replace the cortisol deficiency in classic 21OHD, and 
noncompliance carries a risk of adrenal crisis.29 With at least regular physiologic 
doses of hydrocortisone, their T values will not be in the male range. Enforcing 
and assessing compliance will be a difficult challenge, but steroid analysis in hair 
samples provides a means of long-term assessment.30 In the end, many of these 
women will have higher than normal female circulating T concentrations of 
adrenal origin, but other than instituting the standard of care, there is no 
compelling and endocrinologically sound reason why they should not be in the 
women’s competition. 
F. Athletes with partial AIS 
There is no straightforward answer for these athletes, who in the past were 
evaluated on a case-by-case basis with liberal criteria favoring the athlete. No 
alternative to this approach is apparent. 
G. Transgender athletes 
The current regulations, that transgender athletes should be treated with 
gender-affirming hormone replacement and/or suppression to achieve T values 
in the normal range for their trans-sex, are appropriate and consistent with the 
standard of care. It seems unreasonable that an athlete claims to be a woman 
(gender) but refuses T suppression and estrogen replacement—this behavior is 
inconsistent with being transgendered. 
 
 28. See generally 21-Hydroxylase Deficiency, NAT. INST. OF HEALTH (Jan. 16, 2018), 
https://ghr.nlm.nih.gov/condition/21-hydroxylase-deficiency [https://perma.cc/L3TQ-VUGW] (providing 
more information about 21OHD and the congenital adrenal hyperplasias). 
 29. See Phyllis W. Speiser et al., Congenital Adrenal Hyperplasia Due to Steroid 21-hydroxylase 
Deficiency: an Endocrine Society Clinical Practice Guideline, 95 J. CLINICAL ENDOCRINOLOGY & 
METABOLISM 4133 (2010).  
 30. L. Manenschijn et al., A Novel Tool in the Diagnosis and Follow-Up of (Cyclic) Cushing’s 
Syndrome: Measurement of Long-Term Cortisol in Scalp Hair, 97 J. CLINICAL ENDOCRINOLOGY & 
METABOLISM E1836 (2012), https://www.ncbi.nlm.nih.gov/pubmed/22844063 [https://perma.cc/R2QL-
WUR3] (follow link for full text article at Endocrine Society). 
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V 
POTENTIAL SOLUTIONS 
A. Eliminate the women’s competition 
As an alternative to requiring everyone to compete based on their biological 
sex regardless of their gender identity or how they present, we could throw up 
our hands and say that there is no universally acceptable solution to the 
conundrum and give up. This option would strongly discourage all but the most 
competitive girls and women from seriously embracing sport and would be a 
tragedy for the many female athletes who have experienced personal fulfillment 
from their profession and their successes. This option would also deny countless 
women competing in high school and college sports, the vast majority of whom 
do not become professional athletes, an opportunity to develop valuable 
teamwork and leadership traits in this setting. 
B. Let anybody enter the women’s competition 
This option might sound absurd. Basing participation on gender, not sex, 
would open the floodgates for the many male athletes who will go to extreme 
measures to win medals. Well-publicized studies have demonstrated that many 
elite athletes would take a substance that would guarantee victory at high risk of 
premature death.31 Posing to identify as female (temporarily) is a far easier and 
safer way to gain an advantage. 
C. Let the athletes decide 
Although this might sound democratic, the vast majority of female athletes 
will likely want stringent policing of their competition to maintain fairness from 
their perspective. It is only the minority with DSD that will vote for liberalization, 
and their voices will not be heard. 
D. Develop an algorithm that uses medical science 
Some have argued that DSD athletes in the women’s competition come from 
poor countries without access to medical care and that diagnostic evaluations are 
intrusive and embarrassing. These arguments are unpersuasive and inconsistent 
with the care of non-athletes in these same countries. If an adolescent girl has no 
menses by age sixteen or no menses and no secondary sexual characteristics by 
age fourteen, a complete medical evaluation is indicated. These criteria are the 
same the world over, the basic components of medical history and physical exams 
are available everywhere, and basic laboratory evaluation is available in any 
developed country. Can we provide athletes with expensive training facilities, 
 
 31. See, e.g., Harrison G. Pope, Adverse Health Consequences of Performance-Enhancing Drugs: An 
Endocrine Society Scientific Statement, 35 ENDOCRINE REV. 341 (2014) (reviewing the high prevalence 
of performance-enhancing drug use in elite and amateur athletes alike and noting that the athletes 
consciously accept the increased risks of cardiovascular disease, psychiatric illness, musculoskeletal 
disorders, other serious chronic health effects, and even death associated with their use). 
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gear, coaching staff, and doping tests but deny them the most basic medical care? 
Doing one without the other deprives the athlete of standard basic medical care 
and exploits minors for the benefit of others. If we are placing the athlete’s health 
first, they need to have a diagnosis and proper treatment first and foremost. If we 
only care about winning medals, then we turn a blind eye to an obvious 
disconnect and allow the other women to compete at an unfair disadvantage. 
It is doubtful we will ever arrive at a single criterion for defining athletes who 
qualify for the women’s competition. Additionally, a single unisex competition is 
likely not the best solution. Instead, sport should use a basic screen first, and the 
serum T measurement has performed well because of its physiologic basis. Sports 
should consider lowering the 10 nmol/L cutoff to 3 nmol/L, which is closer to the 
upper limit of the normal female range, if we really are serious about providing 
the best medical care for the athletes because female (sex) athletes with higher 
(abnormal) T levels might suffer adverse health effects without diagnosis and 
proper management. Subsequent to this first screen, an algorithm based on sound 
medical science should distribute athletes fairly into the appropriate 
competitions. Additional testing will include biochemical and genetic testing of 
steroid biosynthetic pathways, AR function, and imaging studies, which a panel 
of experts should design and which will simultaneously provide the standard of 
care for the athletes. Platforms to sequence of all the genes known that contribute 
to DSDs on a single small blood sample are available for <$500, a pittance 
compared to the budget of elite sports. Based on these subsequent results, 
athletes who may not participate in the women’s competition will be identified. 
Other athletes who fail the initial T screen will receive a diagnosis, standard-of-
care therapy, and clearance for the women’s competition. 
These evaluations should be done at home, before any international 
competition, to avoid the public displays of private information that occur when 
athletes are denied proper medical care. There is no more embarrassment for an 
undervirilized male to compete with a female gender in the men’s competition 
than for a trans man to be in the same competition. No one will know the 
difference if they start their international competition in this manner. The 
embarrassment and public exposition is a consequence of accusations that arise 
from attempting to conceal the obvious. 
 
